Healthy Skepticism Library item: 7577

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Smith A.
Senate bill seeks to ban generic payoffs
CNNMoney.com 2007 Jan 17
http://money.cnn.com/2007/01/17/news/companies/senate_generic/index.htm?postversion=2007011711

Full text:

Judiciary Committee to consider bill blocking payments by big drug companies to keep drugs off the market.

NEW YORK (CNNMoney.com) — The Senate Judiciary Committee will consider a bill to get rid of Big Pharma’s payoffs to generic drugmakers that keep their low-cost drugs off the market, according to the committee chairman.

“A drug company will actually pay a generic [company] not to put a drug on the market so they can keep drug prices high,” said the committee chairman, Sen. Patrick Leahy, D-Vt., at a hearing Wednesday.

Leahy said Big Pharma was “driven by greed.”

Committee member Sen. Herbert Kohl, D-Wis., said the bill “will end anti-competitive abuse” and “end payoffs between brand-name competitors and generics.”

Kohl said that these payments – some of them in the hundreds of millions of dollars – are eclipsed by the Big Pharma savings that result from eliminating generic competition. To illustrate the impact of this bill on consumers, Kohl said that even a one percent increase in generic drug use would save Americans some $4 billion in annual healthcare costs.

The bill has bipartisan support. Sen. Charles Grassley, R-Iowa, a committee member, is one of the bill’s co-authors.

The bulk of sales for many drug companies come from name-brand drugs that are protected by patents. When the patents expire on drugs, generic competitors are permitted to produce low-cost versions of them. This can drive down drug prices and revenue by 80 percent in the six months following patent expiration.

Genentech profits, sales surge in 2006
Name-brand drug companies and generic companies often battle over the validity of patents in court. Sometimes this results in the name-brand company paying a settlement to the generic company to keep its product off the market.

But Bill Tauzin, chief executive of PhRMA, an organization that represents the drug industry, said that some of the settlements result in getting generic drugs on the market before the patents expire. Tauzin urged the committee members to use discretion before they eliminate these types of settlements.

“I ask you please not to shoot the good, while you’re trying to kill the bad and the ugly,” said Tauzin, at the hearing. “You ought not to sweep away the good settlements that work to bring generics sooner to the marketplace.”

Pfizer (up $0.10 to $26.87, Charts) is the biggest drug company in the world, followed in the U.S. by Johnson & Johnson (up $0.49 to $67.03, Charts), Abbott Laboratories (up $0.46 to $51.07, Charts) and Merck (up $0.03 to $44.98, Charts). Abbott produces generics as well as name-brand drugs.

The biggest generic drugmaker in the world is Teva Pharmaceuticals (up $0.06 to $32.96, Charts), based in Israel.